Shared conversation
Stock Analysis for Biotechnology and Medicine Companies
Explore stocks in the biotechnology and medicine sectors with market caps below $20 billion that have shown revenue and net income growth, along with their monthly performance metrics.
Read the conversation below. Open the interactive view for charts, attachments, and continuing this conversation.
Aurora
Hello. Do you need help finding some new stocks for your watchlist? Maybe we can find stocks based on their Revenue or Revenue?
User
What stocks with a market cap below $10 billion are up 10% or more for the month and down for the week?
Aurora
Below is a detailed summary of the stocks that met the query criteria, along with a table that includes all 25 stocks with their most important metrics. Each stock ticker is linked to its page for quick reference.
Stocks Meeting Criteria
| Symbol | Current Price | Month Price | Week Price | Market Cap | Month Return (%) | Week Return (%) |
|---|---|---|---|---|---|---|
| WNLV | 0.59 | 0.13 | 0.75 | 168,243,854 | 353.85 | -21.33 |
| OPGN | 1.12 | 0.53 | 1.20 | 11,276,284 | 111.32 | -6.67 |
| BOXL | 0.82 | 0.40 | 1.02 | 8,060,953 | 105.00 | -19.61 |
| SENS | 0.96 | 0.47 | 1.13 | 568,921,109 | 104.26 | -15.04 |
| JEWL | 0.04 | 0.02 | 0.05 | 1,521,906 | 100.00 | -20.00 |
| SANA | 3.22 | 1.65 | 3.38 | 718,925,823 | 95.15 | -4.73 |
| UBX | 2.22 | 1.14 | 2.38 | 37,407,777 | 94.74 | -6.72 |
| EGRX | 0.80 | 0.42 | 0.98 | 10,447,322 | 90.48 | -18.37 |
| ETST | 0.22 | 0.12 | 0.23 | 66,799,896 | 83.33 | -4.35 |
| DTEA | 0.76 | 0.43 | 0.82 | 20,083,802 | 76.74 | -7.32 |
| CYDY | 0.21 | 0.12 | 0.22 | 257,928,720 | 75.00 | -4.55 |
| AGL | 3.34 | 1.92 | 3.61 | 1,376,139,602 | 73.96 | -7.48 |
| RHE | 2.68 | 1.56 | 2.80 | 5,036,387 | 71.79 | -4.29 |
| BMRA | 0.50 | 0.30 | 0.60 | 9,168,497 | 66.67 | -16.67 |
| FNMA | 5.66 | 3.44 | 5.74 | 6,554,775,629 | 64.53 | -1.39 |
| GNLX | 3.95 | 2.41 | 3.96 | 136,425,831 | 63.90 | -0.25 |
| ALCC | 35.30 | 21.85 | 41.82 | 4,309,998,331 | 61.56 | -15.59 |
| MBOT | 1.84 | 1.14 | 2.03 | 31,155,507 | 61.40 | -9.36 |
| IVCP | 11.96 | 7.50 | 12.00 | 54,895,359 | 59.47 | -0.33 |
| GORO | 0.35 | 0.22 | 0.48 | 33,363,732 | 59.09 | -27.08 |
| IVDN | 0.30 | 0.19 | 0.32 | 11,377,201 | 57.89 | -6.25 |
| CRNC | 12.46 | 7.93 | 14.04 | 533,634,251 | 57.12 | -11.25 |
| NARI | 79.67 | 51.80 | 79.74 | 4,664,213,068 | 53.80 | -0.09 |
| SONX | 2.81 | 1.83 | 2.83 | 1,174,718 | 53.55 | -0.71 |
| AMWL | 10.78 | 7.04 | 11.00 | 152,569,297 | 53.12 | -2.00 |
Summary of the Results
Overall Performance:
All stocks in this list show strong monthly returns—with the leading stock, WNLV, experiencing a 353.85% month return. However, every stock also recorded a negative weekly return, suggesting that after a strong monthly rebound, there was some short-term pullback over the last week.Market Cap Consideration:
The stocks have market capitalizations under $10 billion, a criterion of the query. They range widely from small-cap stocks like JEWL with a market cap of about 1.5 million to larger companies like FNMA and ALCC with multi-billion dollar market caps.Price Observations:
A few stocks, such as JEWL and IVDN, offer very low share prices. When looking at such data, it's important to note that percentage returns can be highly volatile, especially with low-priced securities.
Pros and Cons
Pros:
- High monthly returns indicate strong performance over the past month.
- Represents a diverse set of low cap stocks that might provide opportunities for significant gains.
- Provides clear percentage gains for both month-to-date and week-to-date, allowing for performance comparisons.
Cons:
- The negative weekly returns for all stocks may be a concern and suggest a short-term reversals after a strong monthly gain.
- Low-priced stocks come with higher volatility and potential liquidity risks.
- Limited context for the sustainability of these returns; high past performance does not guarantee future gains.
Important Disclaimers
- As an AI, I love analyzing fundamentally strong and intriguing stocks based on technical criteria, but please remember that I might be wrong and that I make mistakes.
- This summary is based on a single snapshot of data. Stock prices and returns can vary significantly, and these metrics are subject to rapid change.
- Always double-check any AI-generated data and analysis, and consider seeking advice from a qualified financial advisor before making any investment decisions.
Use this data as a starting point for further research, and ensure you verify the information with up-to-date, reliable financial sources.
User
What stocks with a market cap below $20 billion are growing in revenue and net income? Only include biology and medicine stocks!
Aurora
Below is a detailed summary of the stocks that met the criteria. In this query, we focused on biotechnology or medicine companies with a market cap below $20 billion that showed improvements in both revenue and net income in 2023 versus 2022. Each stock ticker is linked to its page for easy access.
Stocks Meeting the Criteria
| Symbol | Name | Revenue 2023 | Revenue 2022 | Net Income 2023 | Net Income 2022 | Market Cap | Cap Date |
|---|---|---|---|---|---|---|---|
| TSVT | 2seventy bio Inc | 100,387,000 | 91,496,000 | –217,570,000 | –254,153,000 | 137,225,197 | 2025-01-31 |
| FDMT | 4D Molecular Therapeutics Inc | 20,723,000 | 3,129,000 | –100,837,000 | –107,494,000 | 278,757,511 | 2025-01-31 |
| ANIP | ANI Pharmaceuticals Inc | 486,816,000 | 316,385,000 | 18,779,000 | –47,896,000 | 961,226,880 | 2025-01-31 |
| ACAD | Acadia Pharmaceuticals Inc | 726,437,000 | 517,235,000 | –61,286,000 | –215,975,000 | 3,104,872,686 | 2025-01-31 |
| ADAP | Adaptimmune Therapeutics Plc | 60,281,000 | 27,148,000 | –113,871,000 | –165,456,000 | 905,826,553 | 2025-01-31 |
| ADUS | Addus HomeCare Corporation | 1,058,651,000 | 951,120,000 | 62,516,000 | 46,025,000 | 2,269,540,673 | 2025-01-31 |
| ADMA | Adma Biologics Inc | 258,215,000 | 154,079,692 | 70,929,000 | –65,903,950 | 3,817,702,586 | 2025-01-31 |
| ADVM | Adverum Biotechnologies Inc | 3,600,000 | 0 | –117,165,000 | –154,536,000 | 87,786,394 | 2025-01-31 |
| AIRS | Airsculpt Technologies Inc | 195,917,000 | 168,794,000 | –4,479,000 | –14,679,000 | 277,256,140 | 2025-01-31 |
| AKYA | Akoya Biosciences Inc | 96,633,000 | 74,859,000 | –63,323,000 | –70,641,000 | 144,725,087 | 2025-01-31 |
| ALEC | Alector Inc | 97,062,000 | 0 | –130,391,000 | –133,310,000 | 162,568,124 | 2025-01-31 |
| ALGN | Align Technology Inc | 3,862,260,000 | 3,734,635,000 | 445,053,000 | 361,573,000 | 16,357,231,977 | 2025-01-31 |
| ALGS | Aligos Therapeutics Inc | 15,529,000 | 13,907,000 | –87,679,000 | –96,046,000 | 44,598,370 | 2025-01-31 |
| ALKS | Alkermes plc | 1,663,405,000 | 1,111,795,000 | 355,757,000 | –158,267,000 | 5,101,633,077 | 2025-01-31 |
| FOLD | Amicus Therapeutics Inc | 399,356,000 | 329,233,000 | –151,584,000 | –236,568,000 | 2,862,559,305 | 2025-01-31 |
| AMRX | Amneal Pharmaceuticals Inc - Class A | 2,393,607,000 | 2,212,304,000 | –83,993,000 | –250,044,000 | 2,559,314,992 | 2025-01-31 |
| AMPH | Amphastar Pharmaceuticals Inc | 644,395,000 | 498,987,000 | 137,545,000 | 91,386,000 | 1,676,599,569 | 2025-01-31 |
| AMLX | Amylyx Pharmaceuticals Inc | 380,786,000 | 22,230,000 | 49,271,000 | –198,375,000 | 250,199,689 | 2025-01-31 |
| ANIX | Anixa Biosciences Inc | 210,000 | 0 | –9,811,000 | –13,595,000 | 93,370,900 | 2025-01-31 |
| APLS | Apellis Pharmaceuticals Inc | 396,591,000 | 75,422,000 | –528,628,000 | –652,172,000 | 3,608,641,423 | 2025-01-31 |
| APRE | Aprea Therapeutics Inc | 583,231 | 0 | –14,286,756 | –112,662,027 | 21,250,471 | 2025-01-31 |
| ATR | Aptargroup Inc | 3,487,450,000 | 3,322,249,000 | 284,487,000 | 239,288,000 | 10,457,272,052 | 2025-01-31 |
| APYX | Apyx Medical Corp | 52,349,000 | 44,510,000 | –18,713,000 | –23,184,000 | 49,887,196 | 2025-01-31 |
| AQST | Aquestive Therapeutics Inc | 50,583,000 | 47,680,000 | –7,870,000 | –54,410,000 | 275,358,143 | 2025-01-31 |
| ACLX | Arcellx Inc | 110,319,000 | 0 | –70,690,000 | –188,679,000 | 3,684,107,267 | 2025-01-31 |
Summary of the Results
• All 25 stocks are from the biotechnology/medicine sectors with market caps under $20 billion, and each has shown higher revenue and improved net income in 2023 compared to 2022.
• A few companies, such as ANIP and ADMA, have moved from a negative net income to a positive one or have reduced losses significantly, suggesting some positive operational improvements.
• While many companies have positive revenue growth, several still report negative net income (for example, TSVT, FDMT, and ADAP), which could indicate ongoing challenges in achieving profitability despite increased sales.
• A handful of companies reported zero revenue or net income figures for 2022 (such as ADVM, ALEC, ANIX, APRE, and ACLX). These may be newer or early-stage companies where even a small revenue figure can represent significant growth.
Pros and Cons
• Pros:
– The list highlights companies with robust top-line improvements and comparatively better net income performance in 2023.
– The criteria narrow the focus to biotech/medicine stocks that are growing despite the challenging market conditions, potentially indicating a compelling turnaround or growth story.
• Cons:
– Several stocks still show negative net income, which might signal ongoing operational struggles.
– A few companies with zero figures for 2022 make trend analysis difficult and may require deeper due diligence.
Important Disclaimers
• Always double-check all AI-generated data and analysis with up-to-date and reliable sources.
• This analysis is based on a single data snapshot—financial figures are subject to change rapidly.
• Consider consulting a qualified financial advisor before making any investment decisions.
This information should be used as a starting point for further research into the stocks that meet your criteria.
User
Now let's include only ones that are up for the month!
Aurora
I apologize. I was unable to find any stocks with this criteria. To resolve this, please try one of the following:
- Try starting with something simpler, and then adding more filters.
- Try using a different model (such as Claude-3.5 Sonnet or OpenAI's o1-mini)
- Read about Aurora's capabilities to ensure you're using it correctly.
- Contact support by clicking the 3 dots on the bottom left of the chat and clicking "Report a Bug". You can share a direct link to this chat by clicking the "Share Conversation" button in the same menu.